· Regulatory update
China approves intravenous toripalimab combination for urothelial carcinoma
China’s National Medical Products Administration approved intravenous toripalimab with disitamab vedotin for first-line treatment of locally advanced or metastatic HER2-expressing urothelial carcinoma.
The approval was based on the Phase 3 RC48-C016 trial, registered as NCT05302284.
Read the full company release